Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Nuvation Bioโ€™s IBTROZIโ„ข (taletrectinib), a next-generation oral treatment for advanced ROS1-positive non-small cell lung cancer, has been approved by the U.S. Food and Drug Administration

Nuvation Bio Inc. a global oncology company focused on tackling some of the toughest challenges in cancer treatment, announced that the U.S. Food and Drug Administration (FDA) has approved IBTROZIโ„ข (taletrectinib) for the treatment of adult...

Lubrizol reveals a significant milestone for its innovative, patented Apisolexโ„ข polymer excipient

Lubrizol announces that an Apisolexโ„ข polymer excipient-enabled drug formulation is in Phase 1 clinical trials. Introduced to the market in 2022, Apisolex polymer excipient is a polyamino acid-based polymer that enhances the solubility of BCS Class...

A New Production Line Dedicated to Sterile Hyaluronic Acid Has Been Inaugurated by HTL Biotechnology

On the occasion of National Bioproduction and Biomedicines Day (JNBB), which enjoys the high patronage of the President of the French Republic, HTL Biotechnology confirms its position as a globalleader in the development and production of...

Samsung Bioepis and Organonโ€™s HADLIMAโ„ข Gains FDA Interchangeability Designation, Expanding Access to Adalimumab Alternative

Samsung Bioepis Co., Ltd. and Organon & Co. announced that the US Food and Drug Administration (FDA) has designated the HADLIMAโ„ข (adalimumab-bwwd) high- and low-concentration (40 mg/0.4 mL, 40 mg/0.8 mL) autoinjectors and high-concentration...

Otulfiยฎ (ustekinumab-aauz) by Fresenius Kabi Now FDA-Approved as an Interchangeable Biosimilar

Fresenius Kabi, an operating company of Fresenius, and Formycon AG, announced that the U.S. Food and Drug Administration (FDA) designated Otulfiยฎ (ustekinumab-aauz) as an interchangeable biosimilar to the reference product Stelaraยฎ (ustekinumab)....

Kimeraยฎ Labs named a semifinalist in the $101 million XPRIZE Healthspan competition for pioneering innovations in healthy aging

Kimera Labs, Inc., the pioneer in therapeutic exosome biotechnology, is proud to announce its selection as a semifinalist in the prestigious $101 million XPRIZE Healthspan competition. This milestone recognizes Kimera's groundbreaking work in...

INBRAIN Neuroelectronics has been awarded a โ‚ฌ4 million grant from Spainโ€™s PERTE Chip Program to advance graphene-based brain-computer interfaces

INBRAIN Neuroelectronics, a clinical-stage neurotechnology company developing precision brain-computer interfaces (BCIs) powered by graphene, announced it has been awarded a โ‚ฌ4 million grant by the Spanish Ministry of Industry and Tourism through...

SK Life Science Labs Announces Nature Communications Publication of Breakthrough Molecular Glue Research Advancing Cancer Immunotherapy

SK Life Science Labs, a subsidiary of SK Biopharmaceuticals Co., Ltd., a global biotech focused on the research, development, and commercialization of treatments for cancer and disorders of the central nervous system (CNS), announced the...

Element Science Receives FDA Approval for the Revolutionary Jewelยฎ Patch Wearable Cardioverter Defibrillator

In a significant leap forward in the care of patients with cardiac disease, Element Science is proud to announce that its innovative Jewelยฎ Patch Wearable Cardioverter Defibrillator (Patch-WCD) has received U.S. Food and Drug Administration (FDA)...

Bold Therapeutics Presents Late-Breaking Data on BOLD-100โ€™s Ability to Mitigate Oxaliplatin-Induced Peripheral Neuropathy (OIPN)

Bold Therapeutics Inc., a clinical-stage biopharmaceutical company pioneering novel oncology treatments, announced that its Sr. Director of Preclinical Development, Mark Bazett, PhD, will be presenting a late-breaking poster on BOLD-100's potent...

At the Longhorn Vaccines and Diagnostics Presents Compelling Data on the LHNVD-303 Vaccine for Sepsis Linked to Bacterial Infections

Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented new data on LHNVD-303, the company's composite peptide vaccine for sepsis due to bacterial...

AI Utilized by TNF Pharmaceuticals and Renova Health to Accelerate Drug Development

TNF Pharmaceuticals, Inc. a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, and Renova Health announce the application of AI and machine learning technologies to identify...

BioClear Toenail Fungus Device Under Review: Effective LED Laser for Healthy Nails & Discoloration Treatment

Toenail fungus, medically known as onychomycosis, is more than just a cosmetic issue. It's a persistent condition that affects the appearance, health, and comfort of your feet. What begins as a small yellow or white spot under the nail can...

HighField Biopharmaceuticals Files INDs for Two ADCplexโ„ข Immunoliposomes with Distinct Payloads to Address Limitations of Current ADCs

HighField Biopharmaceuticals, a clinical stage company using lipid-based therapeutics to treat cancer and other diseases, announced today it has filed two investigational new drug (IND) applications (HF158K1 and HFK2) with Chinaโ€™s National Medical...

VCU Collaboration Launched by Galmed Pharmaceuticals to Address Drug Resistance in GI Cancers

Galmed Pharmaceuticals Ltd. a clinical-stage biopharmaceutical company, announced a sponsored research collaboration with Virginia Commonwealth University (VCU) to investigate Aramchol's potential in overcoming drug resistance in gastrointestinal...

Daicel Arbor Biosciences and Element Biosciences announce a new grant opportunity, accelerating agrigenomics

Daicel Arbor Biosciences, a company that offers tools and services to accelerate genomics and synthetic biology research, in collaboration with Element Biosciences, a life sciences company democratizing access to advanced biological tools, is...

PeptiGrowth Inc. Launches Novel Synthetic KGF Alternative Peptide (FGFR2b Agonist)

PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Junichiro Ishizuka) has successfully developed a novel synthetic peptide called "KGF alternative- peptide (FGFR2b agonist)" which is functionally equivalent to recombinant keratinocyte...

Pint Pharma secures ANVISA approval for BESREMiยฎ to treat Polycythemia Vera

Pint Pharma and PharmaEssentia announced that ANVISA (Brazilian Health Regulatory Agency) has approved BESREMiยฎ (ropeginterferon alfa-2b) for the treatment of adult patients with Polycythemia Vera (PV). Polycythemia Vera (PV) is a rare, chronic,...

Developing innovative production technology for the commercialization of 3D cell products, PHC and Cyfuse collaborate

PHC Corporation a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. announce the successful development of a new production technology(*1) for the commercialization of...

Actinium Pharmaceuticals publishes Actimab-A + CLAG-M trial results for relapsed/refractory AML in Leukemia

Actinium Pharmaceuticals, Inc. a pioneer in the development of targeted radiotherapies, announced that results from the clinical trial evaluating Actimab-A in combination with the chemotherapy CLAG-M in patients with relapsed/refractory acute...